Get the Stockscreener App
1.18
5.36%
0.06
After Hours:
1.17
-0.01
-0.85%
Cardiol Therapeutics Inc stock is traded at $1.18, with a volume of 203.75K.
It is up +5.36% in the last 24 hours and down -3.28% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.12
Open:
$1.1
24h Volume:
203.75K
Relative Volume:
0.72
Market Cap:
$96.29M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-3.5531
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
+5.36%
1M Performance:
-3.28%
6M Performance:
-47.56%
1Y Performance:
-22.37%
1-Day Range:
$1.10
$1.21
1-Week Range:
$1.08
$1.22
52-Week Range:
$1.03
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.18 | 96.29M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
163.75 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.13 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.67B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.53 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Cardiol Therapeutics Schedules Annual General Meeting for May 2025 - TipRanks
Financial Comparison: Cardiol Therapeutics (NASDAQ:CRDL) versus Cortexyme (NASDAQ:CRTX) - Defense World
Cardiol Therapeutics to Present at TD Cowen Health Care Conference - TipRanks
Cardiol Therapeutics to present at health care conference - Proactive Investors USA
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile
Cardiol Therapeutics (TSE:CRDL) Hits New 12-Month LowWhat's Next? - MarketBeat
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 - Investing News Network
Cardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Average PT from Analysts - Defense World
Promising Potential of Cardiol Therapeutics’ CRD-38 Justifies Buy Rating Amidst Market Need for HFpEF Treatment - TipRanks
Cardiol Therapeutics Inc. - MENAFN.COM
JACC data highlights Cardiol’s potential to differentiate in HF space - Yahoo Finance
Cardiol Therapeutics reports heart failure treatment progress By Investing.com - Investing.com Nigeria
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure - Proactive financial news
Cardiol Therapeutics reports heart failure treatment progress - Investing.com India
Cardiol Therapeutics Advances Heart Failure Treatment with New Research Publication - TipRanks
Revolutionary Heart Failure Treatment Shows Promise: Top Medical Journal Validates Multiple Therapeutic Benefits - StockTitan
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts (NASDAQ:CRDL) - Seeking Alpha
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis - Newsfile
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot - Newsfile
Biogen (NASDAQ:BIIB) vs. Cardiol Therapeutics (NASDAQ:CRDL) Head to Head Contrast - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.7%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 7.7% – Time to Sell? - Defense World
Cardiol Therapeutics (OTCMKTS:CRTPF) Trading 5.3% Higher – Here’s Why - Armenian Reporter
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Up 5.3% – Time to Buy? - Defense World
Cardiol Therapeutics to present at Oppenheimer Healthcare Conference - Proactive Investors UK
Cardiol Therapeutics to Present at Healthcare Conference, Highlighting Advances in Heart Disease Therapies - TipRanks
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile
Heart Disease Breakthrough: Cardiol Therapeutics Unveils Latest Research at Major Healthcare Summit - StockTitan
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Cardiol Therapeutics (NASDAQ:CRDL) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) PT at $8.40 - MarketBeat
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era - Yahoo Finance
Brokerages Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World
Rodman & Renshaw Begins Coverage on Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock - MSN
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock By Investing.com - Investing.com Canada
Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4%What's Next? - MarketBeat
Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 3.4% – Here’s What Happened - Defense World
Critical Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):